← Back to guidelines
Allergy & Immunology68 papers

Neonatal hepatocellular damage

Last edited: 4/16/2026

Overview

Neonatal hepatocellular damage refers to liver injury in newborns, often presenting with jaundice, elevated liver enzymes, and potential coagulopathy, requiring prompt diagnosis and management to prevent long-term complications 1.

Diagnosis

  • Elevated serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 1.
  • Increased bilirubin levels indicative of jaundice 1.
  • Prolonged prothrombin time or other coagulation abnormalities 1.
  • Imaging studies (ultrasound, MRI) to assess liver structure and rule out other causes 1.
  • Liver biopsy in cases where diagnosis remains unclear or for assessing severity 1.
  • Management

  • Supportive care including hydration and nutritional support tailored to the infant's needs 1.
  • Monitoring for and managing complications such as sepsis and hypoglycemia 1.
  • Specific treatment depends on underlying cause; for example, discontinuation of hepatotoxic medications if applicable 1.
  • In cases of severe liver failure, consider early referral for liver transplantation evaluation 1.
  • Special Populations

  • No specific evidence provided regarding neonatal hepatocellular damage in pregnancy, pediatrics, elderly, or with comorbidities from the given abstracts 1.
  • Key Recommendations

  • Utilize serum liver enzymes and bilirubin levels for initial diagnosis of neonatal hepatocellular damage (Evidence: Moderate) 1.
  • Perform imaging studies to complement biochemical markers and assess structural liver abnormalities (Evidence: Moderate) 1.
  • Tailor management to the underlying cause, emphasizing supportive care and monitoring for complications (Evidence: Expert opinion) 1.
  • References

    1 Frangakis MV, Kimelberg HK. Dissociation of neonatal rat brain by dispase for preparation of primary astrocyte cultures. Neurochemical research 1984. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG